Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05236439Not ApplicableCompleted

Study of a Cilioscleral Interposition Device (CID) SV22 in Patients With Primary Open Angle Glaucoma and Narrow Angle Glaucoma

Role: lead

NCT05625958Not ApplicableActive Not Recruiting

Clinical Study Evaluating the Efficacy and Safety of CID v2.2 in Glaucoma Surgery

Role: lead

NCT04770324Not ApplicableTerminated

Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma (SAFARI 2)

Role: lead

NCT05159817Unknown

Study of an Interposition Supraciliary Implant in Patients With Open Angle Glaucoma

Role: lead

NCT03736655Not ApplicableTerminated

Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma

Role: lead

All 5 trials loaded